Ancheng Shen
Chinese Academy of Sciences
6 Papers
4 Citations
Ancheng Shen is an academic researcher from Chinese Academy of Sciences. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway.
TL;DR: An updated review on the latest progress on the development of small molecule modulators targeting the cGAS‒STING‒TBK1 signaling pathway and their preclinical and clinical use as a new immune stimulatory therapy is provided.
216
Discovery of β-cyclocitral-derived mono-carbonyl curcumin analogs as anti-hepatocellular carcinoma agents via suppression of MAPK signaling pathway.
Haoyi Han,Ali Mohammed Mohammed Alsayed,Yi Wang,Qi Yan,Ancheng Shen,Jianxia Zhang,Yanfei Ye,Zhiguo Liu,Kun Wang,Xiaohui Zheng +9 more
TL;DR: In this article , a series of β-cyclocitral-derived mono-carbonyl curcumin analogs were synthesized and their anticancer properties were evaluated.
9
Structure-Activity relationship study of benzothiophene oxobutanoic acid analogues leading to novel stimulator of interferon gene (STING) agonists.
Ancheng Shen,Xiyuan Li,Yan Zhang,Jing Ma,Ruoxuan Xiao,Xiyuan Wang,Zilan Song,Zhiguo Liu,Meiyu Geng,Ao Zhang,Zuoquan Xie,Chunyong Ding +11 more
TL;DR: Wang et al. as mentioned in this paper performed a structure-activity relationship study based on the benzothiophene oxobutanoic acid scaffold of MSA-2, leading to a series of N-substituted acyloxyamino derivatives with potent STING activating effect.
8
Recent advances in the development of STING inhibitors: an updated patent review
TL;DR: In this article , a review of small-molecule STING inhibitors reported in patents is presented and the available structure-activity relationships (SARs) and molecular mechanisms of action are presented.
8
Discovery of a Highly Potent Oxysterol Receptor GPR183 Antagonist Bearing the Benzo[d]thiazole Structural Motif for the Treatment of Inflammatory Bowel Disease (IBD).
Ruoqing Zeng,Meimiao Fang,Ancheng Shen,Xiaolei Chai,Yumiao Zhao,Mingyao Liu,Lingfeng Zhu,Weiwei Rui,Bo Feng,Liang Hong,Chunyong Ding,Zilan Song,Weiqiang Lu,Ao Zhang +13 more
TL;DR: A structural elaboration focusing on improving the GPR183 antagonist's PK and safety profile based on a reference antagonist NIBR189 demonstrated that compound 33 is a novel and promising GPR183 antagonist suitable for further investigation to treat IBD.